Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BioXcellence

Boehringer Ingelheim headquarters

Boehringer partners with Bactevo on drug discovery

Bactevo will use its TIME platform to identify small molecule lead compounds

Boehringer partners with Bactevo on drug discovery

Bactevo will use its TIME platform to identify small molecule lead compounds

Roche Basel Switzerland

Ocrevus helps Roche stave off biosimilar threat

Its low price strategy for the CD20-targeting antibody is paying off

- PMLiVE

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Offers €15m upfront for the anti-SIRP-alpha antibody and €15m when it reaches phase I testing

- PMLiVE

Reig Jofre and LeanBio launch Syna Therapeutics

The new company will focus on the development of biosimilars

- PMLiVE

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Will launch Herzuma in seven European countries including the UK and Germany

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

Roche Basel Switzerland

Roche faces biosimilar blitz in 2018

Analysts predict copycat competitors will slow the Swiss group’s revenue growth

The tipping point

Accelerating biosimilar uptake through medical education

Novartis day

Novartis doubles down on biosimilars with Biocon alliance

The companies will develop multiple immunology and oncology biosimilars

- PMLiVE

Novartis joins biosimilar Humira push in US

Pharma giant hopes its candidate will follow in the footsteps of Amgen’s Amjevita and BI’s Cyltezo

Biologic or biosimilar: what are prescribers thinking?

Biosimilars are raising their competitive game, but are physicians convinced? And what do they see as the best next moves for biologics?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links